IMMUNOLOGICAL EFFECTS OF ALTERNATIVE WEEKLY INTERFERON-ALPHA-2B AND LOW-DOSE INTERLEUKIN-2 IN PATIENTS WITH CANCER

被引：8
|
作者：
FIORENTINO, B
DISTEFANO, P
GIULIANI, C
AMATETTI, C
TINARI, N
NATOLI, C
GARUFI, C
IACOBELLI, S
机构：
[1] UNIV G DANNUNZIO, CATTEDRA ONCOL MED, VIA DEI VESTINI 66, I-66100 CHIETI, ITALY
[2] UNIV G DANNUNZIO, CATTEDRA ENDOCRINOL, I-66100 CHIETI, ITALY
来源：
BRITISH JOURNAL OF CANCER | 1992年 / 66卷 / 05期
关键词：
D O I：
10.1038/bjc.1992.396
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：981 / 983
页数：3
相关论文
共 50 条
  • [41] EFFECTS OF RECOMBINANT INTERFERON-ALPHA-2B THERAPY IN PATIENTS WITH PROGRESSIVE MS
    KINNUNEN, E
    TIMONEN, T
    PIRTTILA, T
    KALLIOMAKI, P
    KETONEN, L
    MATIKAINEN, E
    SEPPONEN, R
    JUNTUNEN, J
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 87 (06): : 457 - 460
  • [42] Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis
    Lim, Tiong Y.
    Martinez-Llordella, Marc
    Kodela, Elisavet
    Gray, Elisabeth
    Heneghan, Michael A.
    Sanchez-Fueyo, Alberto
    HEPATOLOGY, 2018, 68 (04) : 1649 - 1652
  • [43] Diabetes mellitus induced by low-dose interleukin-2
    Soni, N
    Meropol, NJ
    Porter, M
    Caligiuri, MA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (01) : 59 - 62
  • [44] Low-dose interleukin-2 for systemic lupus erythematosus?
    Wallace, Daniel J.
    LANCET RHEUMATOLOGY, 2019, 1 (01): : E7 - E8
  • [45] Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma
    Karp, SE
    JOURNAL OF IMMUNOTHERAPY, 1998, 21 (01): : 56 - 61
  • [46] IMMUNOLOGICAL STUDY OF HUMAN RECOMBINANT INTERLEUKIN-2 (LOW-DOSE) IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    MARUMO, K
    MURAKI, J
    UENO, M
    TACHIBANA, M
    DEGUCHI, N
    BABA, S
    JITSUKAWA, S
    HATA, M
    TAZAKI, H
    UROLOGY, 1989, 33 (03) : 219 - 225
  • [47] LOW-DOSE CYCLOPHOSPHAMIDE, ALPHA-INTERFERON AND CONTINUOUS INFUSIONS OF INTERLEUKIN-2 IN ADVANCED RENAL-CELL CARCINOMA
    WERSALL, JP
    MASUCCI, G
    HJELM, AL
    RAGNHAMMAR, P
    FAGERBERG, J
    FRODIN, JE
    MERK, K
    LINDEMALM, C
    ERICSON, K
    KALIN, B
    MELLSTEDT, H
    MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1993, 10 (03): : 103 - 111
  • [48] INHALED INTERLEUKIN-2 IN COMBINATION WITH LOW-DOSE SYSTEMIC INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITH PULMONARY METASTATIC RENAL-CELL CARCINOMA - EFFECTIVENESS AND TOXICITY OF MAINLY LOCAL TREATMENT
    HULAND, E
    HEINZER, H
    HULAND, H
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, 120 (04) : 221 - 228
  • [49] CYTOTOXIC INVITRO FUNCTION IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA BEFORE AND AFTER INTERFERON-ALPHA-2B THERAPY - EFFECTS OF ACTIVATION WITH RECOMBINANT INTERLEUKIN-2
    FERUGLIO, C
    ZAMBELLO, R
    TRENTIN, L
    BULIAN, P
    FRANCESCHI, T
    CETTO, GL
    SEMENZATO, G
    CANCER, 1992, 69 (10) : 2525 - 2531
  • [50] WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY IN BREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS
    LISSONI, P
    BARNI, S
    ARDIZZOIA, A
    FOSSATI, V
    PAOLOROSSI, F
    TANCINI, G
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1994, 8 (02): : 53 - 55
12345